Focus Partners Wealth Increases Stock Position in Danaher Corporation $DHR

Key Points

• Focus Partners Wealth increased its holdings in Danaher Corporation by 10.7%, owning 196,682 shares worth approximately $40.3 million after purchasing an additional 19,086 shares.
• Danaher reported a quarterly earnings per share of $1.80, exceeding analysts' expectations of $1.64, with a revenue of $5.94 billion, up 3.4% year-over-year.
• The company announced a quarterly dividend of $0.32 per share to be paid on October 31st, reflecting an annualized yield of 0.7%.

Focus Partners Wealth grew its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 10.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 196,682 shares of the conglomerate's stock after purchasing an additional 19,086 shares during the quarter. Focus Partners Wealth's holdings in Danaher were worth $40,328,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in DHR. Nuveen LLC purchased a new position in shares of Danaher in the first quarter valued at approximately $833,941,000. GAMMA Investing LLC boosted its stake in shares of Danaher by 24,958.2% in the first quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock valued at $383,524,000 after purchasing an additional 1,863,381 shares during the period. Two Sigma Advisers LP boosted its stake in shares of Danaher by 4,248.8% in the fourth quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock valued at $376,347,000 after purchasing an additional 1,601,800 shares during the period. Invesco Ltd. boosted its stake in shares of Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after purchasing an additional 1,450,703 shares during the period. Finally, Point72 Asset Management L.P. boosted its stake in shares of Danaher by 460.6% in the fourth quarter. Point72 Asset Management L.P. now owns 1,348,544 shares of the conglomerate's stock valued at $309,558,000 after purchasing an additional 1,107,998 shares during the period. Hedge funds and other institutional investors own 79.05% of the company's stock.

Danaher Stock Down 0.8%

Shares of Danaher stock opened at $192.85 on Thursday. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90. The company has a 50 day moving average of $201.62 and a 200 day moving average of $199.15. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $138.09 billion, a P/E ratio of 41.03, a P/E/G ratio of 2.71 and a beta of 0.75.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion for the quarter, compared to analysts' expectations of $5.83 billion. During the same quarter last year, the company earned $1.72 earnings per share. The firm's revenue for the quarter was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, research analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.7%. Danaher's dividend payout ratio (DPR) is presently 27.23%.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 11.10% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently commented on DHR shares. Robert W. Baird raised their price objective on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research note on Friday, July 18th. Evercore ISI lowered their price objective on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target for the company in a research note on Friday, July 11th. Wells Fargo & Company decreased their price target on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 23rd. Finally, UBS Group decreased their price target on shares of Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a research note on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $246.35.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.